Indacaterol/mometasone

From WikiProjectMed
Jump to navigation Jump to search

Indacaterol/mometasone
Combination of
IndacaterolBeta-2 adrenergic receptor agonist
MometasoneCorticosteroid
Clinical data
Trade namesAtectura Breezhaler, Bemrist Breezhaler
Other namesQMF149, IND/MF
License data
Routes of
administration
Inhalation
ATC code
Legal status
Legal status
Identifiers
KEGG

Indacaterol/mometasone, sold under the brand name Atectura Breezhaler among others, is a fixed-dose combination medication for the treatment of asthma in adults and adolescents twelve years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2 agonists.[2]

The most common side effects include worsening of asthma and nasopharyngitis (inflammation in the nose and throat).[2] Other common side effects include upper respiratory tract infection (nose and throat infections) and headache.[2] Indacaterol/mometasone was approved for medical use in the European Union in May 2020,[2] and in Japan in June 2020.[6]

References

  1. ^ "Regulatory Decision Summary - Atectura Breezhaler". Health Canada. 23 October 2014. Retrieved 7 June 2022.
  2. ^ a b c d e "Atectura Breezhaler EPAR". European Medicines Agency (EMA). 24 March 2020. Retrieved 23 June 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  3. ^ "Bemrist Breezhaler EPAR". European Medicines Agency. 24 March 2020. Retrieved 4 March 2023.
  4. ^ "Atectura Breezhaler Product information". Union Register of medicinal products. Retrieved 3 March 2023.
  5. ^ "Bemrist Breezhaler Product information". Union Register of medicinal products. Retrieved 3 March 2023.
  6. ^ "Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options". Novartis (Press release). 29 June 2020. Archived from the original on 26 July 2020. Retrieved 25 July 2020.

External links